Weight management has become one of the most commercially attractive and heavily monitored healthcare categories in the UK. Demand for medicated treatment is high, but the route from advert to consultation is being scrutinised across prescription medicine rules, social responsibility, platform policies, clinical governance and health data.
WLW FUTURE reviewed the ASA’s 2026 enforcement report, current MHRA advertising decisions, the joint MHRA, ASA and GPhC warning on newly licensed and unlicensed weight management medicines and current advertising policies from Google, Meta and TikTok. The commercial requirement is to build demand around the service and clinical journey without turning the advert or landing page into public promotion of a prescription only medicine.
Research boundary
This is a B2B marketing and digital intelligence report. Regulatory and platform sources are linked throughout. Providers should obtain appropriate legal, regulatory, pharmacy and clinical advice for specific campaigns and treatment pathways.
This is a B2B marketing and digital intelligence report. Regulatory and platform sources are linked throughout. Providers should obtain appropriate legal, regulatory, pharmacy and clinical advice for specific campaigns and treatment pathways.
95k+unique paid online ads captured during ASA weight loss POM monitoring
35kads in the dataset related specifically to weight management services
~900ads from 38 advertisers were assessed as likely to breach the POM rules
99%compliance with the ASA Enforcement Notice was reached by January 2026
The headline findings for weight management marketing in 2026
Indirect medicine references can still be promotion
MHRA guidance published in June 2026 says references such as weight loss injections or GLP-1 medication can amount to public POM promotion depending on context, prominence and the customer journey.
The landing page is part of the advert
Current ASA rulings show that an apparently service led advert can still create exposure when the destination immediately compares named medicines, prices or branded injection pens.
Price led medicine journeys are high risk
Recent enforcement includes offers which use price drops, introductory pricing and comparisons to push users towards prescription weight management medicines.
Influencers do not create a separate rulebook
Influencer, affiliate and organic promotional content can still be advertising. Medicine naming, free treatment and transformation claims need the same scrutiny as paid media.
Body image and rapid outcome claims need judgement
Weight management marketing can move quickly from useful health information into pressure, unrealistic transformation claims or language which exploits insecurity.
Platform eligibility differs from UK compliance
A campaign can satisfy UK medicine advertising law and still breach Google, Meta or TikTok policy. Certification, health targeting and medicine restrictions should be checked independently.
The 2026 enforcement picture is unusually strong
The ASA’s April 2026 enforcement report analysed more than 95,000 unique paid ads from 44 advertisers across Google, Meta, TikTok and display. Around 35,000 related to weight management. Around 900 ads from 38 advertisers were assessed as likely breaches because they named or implied POMs or used branded injection pen imagery. By January 2026 the ASA reported 99% compliance with its Enforcement Notice. ASA enforcement report
On 18 June 2026 the MHRA, ASA and GPhC issued a joint warning covering promotion of newly licensed prescription only medicines and unlicensed medicines for weight management. Joint regulator warning
Enforcement is moving from obvious brand names to the whole promotional context
The June 2026 MHRA decision on medicinal treatment services for weight loss makes clear that indirect wording can still amount to public POM promotion when the surrounding context points users towards prescription medicines.
AI monitoringASA Active Ad Monitoring allows regulators to review paid advertising at scale rather than relying only on complaints.ASA
Indirect referencesMHRA says references such as weight loss injections or GLP-1 medication can be promotional depending on context.MHRA
Joint actionMHRA, ASA and GPhC jointly warned businesses about newly licensed POMs and unlicensed weight management medicines in June 2026.GOV.UK
What weight management services can advertise
| Offer | Starting position | Main issue | Risk |
|---|---|---|---|
| General weight management consultation | Can generally be promoted subject to claims, provider scope and platform rules | Keep the advert focused on assessment, support and service rather than implying a specific POM | Manageable |
| Lifestyle and behavioural programme | Can generally be promoted where claims are accurate and evidenced | Avoid guaranteed weight loss, unrealistic speed or misleading before and after presentation | Review |
| Prescription treatment service | The service can be promoted while public POM promotion remains prohibited | Medicine names, indirect GLP-1 references, branded imagery, prices and landing pages | High scrutiny |
| Named GLP-1 or other POM | Cannot be advertised to the public | Direct and indirect product promotion, efficacy claims, offers and influencer content | High risk |
| OTC weight management product | May be advertised where authorised and claims comply with medicine or food rules as applicable | Product status, authorised indications, evidence and platform eligibility | Review |
Interactive weight management marketing risk checker
Check the service, channel, message and destination together
Choose the closest options. The result is a marketing screening tool based on the public sources reviewed for this report.
1. What are you promoting?
2. Which channel is central?
3. What does the creative emphasise?
4. What appears before clinical assessment?
Lower risk starting point
Keep the service, claims and destination aligned
A service led campaign with no POM promotion has a more manageable starting position.
GLP-1 and prescription medicine marketing needs a consultation led architecture
MHRA guidance says treatment service advertising may be acceptable when the service is the focus and the material is not likely to lead consumers to seek a particular POM. The June 2026 decision also explains that indirect references can become promotional when they clearly point towards prescription weight management medicines. MHRA June 2026
1. NeedThe user arrives around weight management, health goals or a service need rather than a promoted medicine.
2. ServiceThe provider explains eligibility, consultation, clinical support, pricing structure and what the service includes.
3. AssessmentClinical history, identity, suitability and relevant measurements are reviewed before treatment decisions.
4. OptionsBalanced treatment information follows assessment and should not operate as a promotional comparison page.
5. Follow upMonitoring, side effect support, dose review, lifestyle support and escalation complete the service journey.
Google, Meta and TikTok create different acquisition boundaries
| Channel | Current position | Commercial implication |
|---|---|---|
| Healthcare and medicines policies restrict prescription drug promotion and health based personalised advertising. | Resolve certification and landing page structure before scaling paid search. | |
| Meta | General telehealth can be advertised but direct prescription drug advertising is limited to eligible countries which do not currently include the UK. | Keep UK weight management acquisition focused on the service rather than a prescription medicine. |
| TikTok | TikTok’s June 2026 healthcare policy does not allow prescription medicine advertising. | Check service eligibility before production and avoid medicine led creative. |
| Influencers | Commercial content remains advertising and can also engage POM promotion and disclosure rules. | Free treatment, affiliate relationships and transformation claims need a formal review route. |
Pricing, urgency and transformation claims are commercial pressure points
Separate service fees from medicine promotion
Explain consultation and programme costs without using price as a shortcut to promote a POM.
Review transformation language
Before and after creative, ideal body messaging and confidence claims should be reviewed for evidence and social responsibility.
Control influencer activity
Give creators explicit boundaries around medicine naming, claims, free treatment and commercial disclosure.
Health data changes the rules for CRM and remarketing
Weight management funnels naturally collect BMI, medication, health condition and treatment preference information. ICO guidance identifies health information as special category data and says organisations should generally have explicit consent when using special category information for direct marketing. ICO guidance
The strongest customer journey sells the service before it asks for trust
Own the service questions
Answer eligibility, process, support, cost and follow up questions before pushing the customer into a form.
Make clinical governance visible
Show who provides care, how prescribing works and what checks take place before treatment.
Design assessment for completion and confidence
Explain why sensitive information is needed and what happens after each step.
Measure suitable conversion
Track appropriate consultations, treatment starts, retention and support as well as media leads.
Benchmark your current weight management marketing
Current benchmark score
0/10
Start with the service architecture
Connect treatment status, POM promotion, customer journey, platform eligibility, health data and commercial measurement before scaling acquisition.
Where compliant weight management growth remains
Own high intent search
Build useful pages around eligibility, service process, pricing, monitoring and support.
Separate medicated and non medicated journeys
Different pathways reduce regulatory ambiguity and improve relevance.
Turn governance into trust
Show prescribing standards, clinician expertise and follow up as reasons to choose the provider.
Improve assessment conversion
Make the pathway clearer without removing the checks required for safe care.
Measure retention and suitability
Connect acquisition to appropriate treatment, continuation and service profitability.
Build AI citation readiness
Use expert reviewed explanations, evidence and structured service content.
WLW FUTURE weight management digital opportunity review
See where your weight management journey is exposed and where it can grow
WLW FUTURE can review your website, search visibility, AI visibility, advertising, treatment journeys, health data use, competitor position and conversion routes together.
Request a weight management digital opportunity reviewFrequently asked questions
Can UK providers advertise weight management services?
Yes, service and consultation marketing can be possible. Public promotion of prescription only medicines remains prohibited.
Can adverts say GLP-1 or weight loss injections?
MHRA guidance published in June 2026 says indirect references can amount to POM promotion depending on context.
Can a provider advertise a named weight loss medicine?
Prescription only medicines cannot be advertised to the public in the UK.
Can health data from an eligibility form be used for remarketing?
Health information is special category data and using it for direct marketing can require explicit consent and an appropriate lawful basis.
Sources and methodology
- ASA Enforcement Report: weight loss prescription only medicines. Published 2 April 2026.
- MHRA medicinal treatment services for weight loss, June 2026.
- MHRA, ASA and GPhC joint warning.
- MHRA: Advertise your medicines.
- Google healthcare and medicines policy.
- Meta drugs and pharmaceuticals policy.
- TikTok healthcare and pharmaceuticals policy.
- ICO direct marketing guidance.
Commercial methodology: The risk checker and benchmark are WLW FUTURE planning tools derived from current public evidence. They do not certify regulatory compliance.
